Association of Baseline Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
J Urol
; : 101097JU0000000000004117, 2024 Jun 25.
Article
de En
| MEDLINE
| ID: mdl-38917450
ABSTRACT
PURPOSE:
The purpose of our study was to evaluate the association of baseline MRI Prostate Imaging Reporting and Data System (PI-RADS) score with biopsy reclassification in a multicenter active surveillance (AS) cohort. MATERIALS ANDMETHODS:
We identified men in the Michigan Urological Surgery Improvement Collaborative registry (46 hospital-based/academic/private practice urology groups) with National Comprehensive Cancer Network (NCCN) low-risk and favorable intermediate-risk prostate cancer who underwent MRI within 6 months before or after initial biopsy and enrolled in AS from June 2016 to January 2021. The primary objective was to determine the association of baseline MRI PI-RADS score (≥4 lesion) with reclassification to high-grade prostate cancer (≥grade group 3) on surveillance biopsy. Multivariable Cox proportional hazards regression models were constructed and adjusted for pathologic, MRI, and clinical/biopsy factors, with landmark time of 6 months from diagnostic biopsy. We included an interaction term between PI-RADS score and NCCN group in the Cox model.RESULTS:
A total of 1491 men were included with median age 64 years (IQR 59-69) with median follow-up 11.0 months (IQR 6.0-23.0) after landmark. Baseline PI-RADS ≥ 4 lesion was associated with an increased hazard of biopsy reclassification (HR 2.3 [95% CI 1.6-3.2], P < .001), along with grade group 2 vs 1 (HR 2.5 [95% CI 1.7-3.7], P < .001), and increasing age (per 10 years; HR 1.8 [95% CI 1.4-2.4], P < .001). The interaction between NCCN risk group with MRI findings was not significant (P = .7).CONCLUSIONS:
In this multicenter cohort study of real-world data, baseline MRI PI-RADS score was significantly associated with early biopsy reclassification in men undergoing AS with NCCN low- or favorable intermediate-risk prostate cancer.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
J Urol
Année:
2024
Type de document:
Article